Alise Reicin

Alise is a 20+ year R&D veteran of the pharmaceutical industry and served most recently as President of Global Clinical Development at Celgene. In her distinguished career at Merck, EMD Serono and Celgene, Alise led teams and functions that enabled the approval of >15 novel drugs and indications that now account for over $20B in global sales across a variety of disease areas including autoimmune (Zeposia®, Arcoxia®, Mavenclad®, Simponi®) and oncology (Keytruda®, Inrebic®, Reblozyl®, Bavencio®, Breyanzi®). She joined Tectonic in 2020 as President and CEO, and holds an M.D. with honors from Harvard Medical School where she was part of the Health Science and Technology program (HST). Alise served as a faculty member at Columbia University’s Medical School for a decade, where she did research and specialized in the treatment of infectious diseases.